Calcium channel blockers decrease the risk of active tuberculosis
The use of calcium channel blockers (CCBs) decreased the risk of active tuberculosis, according to a population-based analysis.
In this nested case-control study, researchers analyzed 8164 new active tuberculosis cases and 816,400 control cases to evaluate whether CCBs modify the risk of active tuberculosis disease.
After adjusting for disease risk score, CCBs use was associated with a 32% decrease in the risk of active tuberculosis (relative risk [RR], 0.68 [95% CI, 0.58–0.78]). Dihydropyridine CCB use was associated with a lower risk of tuberculosis (RR, 0.63 [95% CI, 0.53–0.79]) than nondihydropyridine CCBs (RR, 0.73 [95% CI, 0.57–0.94]), compared with cases where CCBs were not used. Use of β-blockers (RR, 0.99 [95% CI, 0.83–1.12]) or loop diuretics (RR, 0.88 [95% CI, 0.62–1.26]) was not associated with lower a risk of tuberculosis.
Results from a subgroup analysis found that the risk of tuberculosis associated with CCBs use was comparable among patients with heart failure or cerebrovascular diseases.
Use of calcium channel blockers and risk of active tuberculosis disease: A population-based analysis. Hypertension. 2020; Epub Ahead of Print.